ClinicalTrials.gg
CompletedNCT01340053Updated Oct 15, 2019Results posted

A Study to Evaluate the Safety and Efficacy of RDX5791 for the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS-C)

A Phase 2 interventional study of RDX5791 in Constipation Predominant Irritable Bowel Syndrome, sponsored by Ardelyx. Completed at 16 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-10-15.

Sponsored by Ardelyx · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
186
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing tenapanor in Constipation — 3 open to participants now, 4 under way, 3 of them phase 3. tenapanor · Constipation.

Enrollment
6th of 11
186 · median 186
Started
2011
the only one that year
Phase 2
3 of 11
1 open now
Registered
1st of 11
by date
Lead sponsor
9 of 11
Ardelyx

Among the 11 studies testing tenapanor in Constipation, this one is the 6th largest by enrollment, is the only one that started in 2011, is one of 3 in phase 2, and was the 1st registered.

Constipation

1,047 studies on the registry are indexed under Constipation; 161 are open to participants now.

Browse Constipation studies →

Open to participants now

3 of the 11 studies testing tenapanor in Constipation are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

About tenapanor

tenapanor: first FDA approval 2019 (IBSRELA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 99 Constipation studies recruiting now, 32 (32%) set no upper age limit and 52 (53%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing tenapanor in Constipation, or all of them as a file.
02

Study summary

This is a multi-center, Phase 2, randomized, double-blind, placebo controlled study of RDX5791 in subjects with IBS-C. Patients who are 18 to 75 years old, meeting the definition of IBS-C as defined by the Rome III Criteria for the Diagnosis of IBS will undergo a battery of screening procedures to determine eligibility for the trial.

The study will consist of a 2-week treatment-free screening period, a 4-week blinded treatment period, and a 2-week treatment-free follow-up period.

03

Conditions studied

  • Constipation Predominant Irritable Bowel Syndrome
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject meets Rome III criteria for IBS-C
  • If > 50 years old, colonoscopy evaluation within 10 years
  • All ages, negative colonoscopy if any "warning symptoms"
  • Active disease during 2-week screening period
  • Compliant with IVRS

Exclusion criteria

Exclusion Criteria:

  • Subjects has IBS-D, IBS-M or un-subtyped IBS according to Rome III criteria
  • Diagnosis or treatment of any clinically symptomatic biochemical or structural abnormality of the GI tract
  • Use of medications that are known to affect stool consistency
  • Subject has any protocol-excluded or medical or surgical history that could confound the study assessments or prevent completion of study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
186 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Capsule that is identical in size and color to other treatments

    Drug: RDX5791

  • Experimental
    Low Dose

    10 mg capsule of tenapanor

    Drug: RDX5791

  • Experimental
    Mid Dose

    30 mg capsule of tenapanor

    Drug: RDX5791

  • Experimental
    High Dose

    100 mg capsule of tenapanor

    Drug: RDX5791

Interventions

06

What researchers measure

Primary outcomes

  1. Complete Spontaneous Bowel Movement (CSBM) Frequency Change From Baseline

    Patients complete a phone diary daily. They are asked "how many bowel movements have you had today?" they are then asked for each spontaneous bowel movement (unaided with laxative use) wether there was its was a complete evacuation. if it was then it is a complete spontaneous bowel movement. All CSBMs are added and adjusted for a mean compete sponteneous bowel movement.

    Time frame: Baseline and Week 4

Secondary outcomes

  1. Spontaneous Bowel Movement (SBM) Frequency Change From Baseline

    Time frame: baseline and week 4

07

Results

Posted Oct 15, 2019

Participant flow

Participant flow — Overall Study
MilestonePlacebo10mg30 mg100 mg
Started47464746
Completed43444343
Not completed4243

Outcome measures

PrimaryComplete Spontaneous Bowel Movement (CSBM) Frequency Change From Baseline

Patients complete a phone diary daily. They are asked "how many bowel movements have you had today?" they are then asked for each spontaneous bowel movement (unaided with laxative use) wether there was its was a complete evacuation. if it was then it is a complete spontaneous bowel movement. All CSBMs are added and adjusted for a mean compete sponteneous bowel movement.

Time frame:
Baseline and Week 4
Reported as:
Mean · number of bowel movements/week
Complete Spontaneous Bowel Movement (CSBM) Frequency Change From Baseline
number of bowel movements/weekPlaceboLow DoseMid DoseHigh Dose
Complete Spontaneous Bowel Movement (CSBM) Frequency Change From Baseline1.01 ± 2.031.50 ± 2.091.54 ± 2.101.57 ± 2.50
SecondarySpontaneous Bowel Movement (SBM) Frequency Change From Baseline
Time frame:
baseline and week 4
Reported as:
Mean · change in number of bowel movements
Spontaneous Bowel Movement (SBM) Frequency Change From Baseline
change in number of bowel movementsPlaceboLow DoseMid DoseHigh Dose
Spontaneous Bowel Movement (SBM) Frequency Change From Baseline1.58 ± 2.512.37 ± 2.272.97 ± 3.132.81 ± 3.14

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/47 (0%)0/47 (0%)0/47 (0%)
Low Dose0/46 (0%)2/46 (4.3%)0/46 (0%)
Mid Dose0/47 (0%)0/47 (0%)0/47 (0%)
High Dose0/46 (0%)0/46 (0%)0/46 (0%)
Most frequent serious events
Most frequent serious events
EventPlaceboLow DoseMid DoseHigh Dose
cholecystitisGastrointestinal disorders0/471/460/470/46
appendicitisGastrointestinal disorders0/471/460/470/46

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboLow DoseMid DoseHigh DoseTotal
Mean47.9 ± 11.9744.4 ± 14.1546.5 ± 9.4943.5 ± 12.3145.6 ± 12.11
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboLow DoseMid DoseHigh DoseTotal
Female39423937157
Male848929
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboLow DoseMid DoseHigh DoseTotal
Hispanic or Latino365822
Not Hispanic or Latino44404238164
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboLow DoseMid DoseHigh DoseTotal
American Indian or Alaska Native00000
Asian12003
Native Hawaiian or Other Pacific Islander00000
Black or African American12591036
White34393836147
More than one race00000
Unknown or Not Reported00000
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)PlaceboLow DoseMid DoseHigh DoseTotal
Mean28.02 ± 5.5627.40 ± 6.9728.58 ± 6.1028.10 ± 4.1428.03 ± 5.74
08

Study locations

16 sites
  • Ardelyx Investigational Site
    San Diego, California 92108, United States
  • Ardelyx Investigational Site
    Jupiter, Florida 33458, United States
  • Ardelyx Investigational Site
    Pinellas Park, Florida 33782, United States
  • Ardelyx Investigational Site
    Rockford, Illinois 61107, United States
  • Ardelyx Investigational Site
    Mission, Kansas 66202, United States
  • Ardelyx Investigational Site
    Monroe, Louisiana 71201, United States
  • Ardelyx Investigational Site
    Annapolis, Maryland 21401, United States
  • Ardelyx Investigational Site
    Chesterfield, Michigan 48047, United States
  • Ardelyx Investigational Site
    Saint Louis, Missouri 63128, United States
  • Ardelyx Investigational Site
    Brooklyn, New York 11214, United States
  • Ardelyx Investigational Site
    Greensboro, North Carolina 27408, United States
  • Ardelyx Investigational Site
    Oklahoma City, Oklahoma 73104, United States
  • Ardelyx Investigational Site
    Simpsonville, South Carolina 29681, United States
  • Ardelyx Investigational Site
    Bristol, Tennessee 37620, United States
  • Ardelyx Investigational Site
    Ogden, Utah 84405, United States
  • Ardelyx Investigational Site
    Lynchburg, Virginia 24502, United States
09

References and documents

Related links

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2011, a primary completion of Dec 2011 and a completion of Feb 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2019, 7 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2011
First posted
Apr 22, 2011
Start
May 2011
Primary completionActual
Dec 2011
CompletionActual
Feb 2012
Results first posted
Oct 15, 2019
Last update
Oct 15, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01340053
Lead sponsor
Ardelyx
Responsible party
Sponsor
First posted
Apr 22, 2011
Start date
May 2011
Primary completion
Dec 2011
Completion
Feb 2012
Results posted
Oct 15, 2019
Last update
Oct 15, 2019

Study contacts

David P Rosenbaum, Ph.D.
study chair · Ardelyx

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenapanor

Start the discussion